Spark Therapeutics is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases.

Employee Rating

2.3More
TypePublic
HQPhiladelphia, US
Founded2013
Size (employees)213 (est)
Websitesparktx.com
Spark Therapeutics was founded in 2013 and is headquartered in Philadelphia, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Spark Therapeutics

Jeffrey D. Marrazzo

Jeffrey D. Marrazzo

Co-Founder, President and CEO
J. Fraser Wright

J. Fraser Wright

Scientific Co-Founder and CTO
Katherine A. High

Katherine A. High

Scientific Co-Founder
Show more

Spark Therapeutics Office Locations

Spark Therapeutics has an office in Philadelphia
Philadelphia, (HQ)
3737 Market St
Show all (1)
Report incorrect company information

Spark Therapeutics Financials and Metrics

Spark Therapeutics Revenue

Spark Therapeutics's revenue was reported to be $12.07 m in FY, 2017
USD

Revenue (Q3, 2018)

10.7m

Gross profit (Q3, 2018)

10.4m

Gross profit margin (Q3, 2018), %

97%

Net income (Q3, 2018)

(47.4m)

EBIT (Q3, 2018)

(51.7m)

Market capitalization (4-Dec-2018)

1.5b

Closing stock price (4-Dec-2018)

39.2

Cash (30-Sep-2018)

161.6m

EV

1.4b
Spark Therapeutics's current market capitalization is $1.5 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

633.9k22.1m20.2m12.1m

Revenue growth, %

3380%(9%)

General and administrative expense

7.9m23.4m48.1m111.1m

R&D expense

16.4m46.0m86.4m135.2m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

2.3m1.3m1.3m1.3m1.3m1.3m1.3m1.5m1.9m15.7m25.2m10.7m

Cost of goods sold

121.0k269.0k318.0k

Gross profit

15.6m24.9m10.4m

Gross profit Margin, %

99%99%97%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

74.6m293.5m58.9m96.7m

Accounts Receivable

244.4k16.9m16.8m

Current Assets

77.4m311.6m314.6m533.2m

PP&E

12.7m17.0m19.8m61.7m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

234.4m223.0m212.2m275.0m225.0m90.6m27.5m36.8m146.4m127.7m201.1m161.6m

Accounts Receivable

669.4k933.1k1.3m812.8k1.2m1.0m5.9m5.0m

Inventories

5.6m12.7m20.7m

Current Assets

235.9m225.1m214.3m277.8m335.3m309.2m263.4m226.3m489.1m621.0m691.6m635.2m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(24.3m)(47.1m)(123.7m)(253.5m)

Depreciation and Amortization

169.8k1.7m3.6m4.9m

Accounts Payable

2.3m9.1m10.0m13.0m

Cash From Operating Activities

10.4m(47.5m)(80.4m)(154.5m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(9.7m)(24.1m)(41.0m)(25.6m)(54.3m)(86.8m)(52.3m)(126.6m)(191.7m)(46.4m)33.8m(13.6m)

Depreciation and Amortization

370.6k797.2k1.2m744.1k1.7m2.6m1.0m2.2m3.5m1.5m3.1m4.8m

Inventories

(5.6m)(12.7m)(20.7m)

Accounts Payable

870.4k3.2m7.7m(1.1m)(2.0m)4.2m(2.7m)4.8m839.4k(8.4m)(8.0m)(877.0k)
USDY, 2018

EV/EBIT

-26.4 x

EV/CFO

-48.8 x

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.5 x
Show all financial metrics

Spark Therapeutics Operating Metrics

FY, 2016

Patents and Patent Applications

297
Show all operating metrics
Report incorrect company information

Spark Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Spark Therapeutics News and Updates

Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition

Preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show dramatic reductions in bleeds and infusions for first 12 participants with an encouraging safety profile, as of Nov. 2, 2018, data cutoff

Gene Therapy Market Growth Analysis Till 2025: AveXis, Vineti, Solid Biosciences., Spark Therapeutics, Inc., CHIMERON BIO, RENOVA THERAPEUTICS

Global Gene Therapy Market Analysis to 2025 is a specialized and in-depth study of the gene therapy industry with a focus on the global market trend. Posted via Industry Today. Follow us on Twitter @IndustryToday

Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress

PHILADELPHIA, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for the third quarter of 2018 and recent business pr…

Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA® (voretigene neparvovec-rzyl) at American Academy of Ophthalmology Annual Meeting

Use of different measurement for best-corrected visual acuity of participants in the Phase 3 clinical trial of LUXTURNA achieved statistically significant improvement versus control group

Spark Therapeutics Annuncia il Parere positivo del CHMP per la Terapia Genica una tantum LUXTURNA® (voretigene neparvovec) nell’Unione europea

LUXTURNA diventerebbe la prima terapia genica per una malattia genetica approvata sia negli USA sia nella UE LUXTURNA sarebbe la prima e unica terapia genica approvata nell’UE per il trattamento di quei pazienti che presentano un numero sufficiente di cellule retiniche vitali e che hanno …

Spark Therapeutics gibt zustimmende Bewertung des Ausschusses für Humanarzneimittel für die einmalig verabreichte Gentherapie LUXTURNA® (Voretigen Neparvovec) in der Europäischen Union bekannt

                             LUXTURNA wäre die erste Gentherapie für eine genetische Erkrankung, die sowohl in den USA als auch in der EU zugelassen ist
Show more
Report incorrect company information

Spark Therapeutics Blogs

Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights

Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights Content Import Tue, 10/30/2018 - 07:32 Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Resu…

Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases

Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases Content Import Thu, 10/25/2018 - 07:34 Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for…

Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate

Data from IND-enabling studies in three species support moving SPK-3006 into the clinic in 2019 PHILADELPHIA , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today

Spark Therapeutics Company Life and Culture

Report incorrect company information

Spark Therapeutics Frequently Asked Questions

  • When was Spark Therapeutics founded?

    Spark Therapeutics was founded in 2013.

  • Who are Spark Therapeutics key executives?

    Spark Therapeutics's key executives are Jeffrey D. Marrazzo, J. Fraser Wright and Katherine A. High.

  • How many employees does Spark Therapeutics have?

    Spark Therapeutics has 213 employees.

  • What is Spark Therapeutics revenue?

    Latest Spark Therapeutics annual revenue is $12.1 m.

  • What is Spark Therapeutics revenue per employee?

    Latest Spark Therapeutics revenue per employee is $56.6 k.

  • Who are Spark Therapeutics competitors?

    Competitors of Spark Therapeutics include ImaginAb, Guardant Health and Orgenesis.

  • Where is Spark Therapeutics headquarters?

    Spark Therapeutics headquarters is located at 3737 Market St, Philadelphia.

  • Where are Spark Therapeutics offices?

    Spark Therapeutics has an office in Philadelphia.

  • How many offices does Spark Therapeutics have?

    Spark Therapeutics has 1 office.